Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2019

01-02-2019 | PRECLINICAL STUDIES

Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer

Authors: Maha M. Eissa, Cherine A. Ismail, Mervat Z. El-Azzouni, Amany A. Ghazy, Mona A. Hadi

Published in: Investigational New Drugs | Issue 1/2019

Login to get access

Summary

Considerable evidence indicates a negative correlation between the prevalence of some parasitic infections and cancer and their interference with tumor growth. Therefore, parasitic antigens seem to be promising candidates for cancer immunotherapy. In this study, the therapeutic efficacy of autoclaved Schistosoma mansoni and Trichinella spiralis antigens against a colon cancer murine model was investigated. Both antigens showed immunomodulatory potential, as evidenced by a significant decrease in serum IL-17, a significant increase in serum IL-10, and the percentage of splenic CD4+T-cells and intestinal FoxP3+ Treg cells. However, treatment with S. mansoni antigen yielded protection against the deleterious effect of DMH-induced colon carcinogenesis only, with a significant decrease in the average lesion size and number of neoplasias per mouse. For the first time, we report an inhibitory effect of S. mansoni antigen on the progression of chemically induced colon carcinogenesis, but the exact mechanism has yet to be clarified. This anti-tumor strategy could introduce a new era of medicine in which a generation of anticancer vaccines of parasitic origin would boost the therapy for incurable cancers.
Literature
1.
2.
3.
Darani HY, Yousefi M (2012) Parasites and cancers: parasite antigens as possible targets for cancer immunotherapy. Future Oncol 8(12):1529–1535CrossRefPubMed
4.
5.
Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, et al (2011) Antitumor effect of malaria parasite in a murine lewis lung cancer model through induction of innate and adaptive immunity. PLoS ONE 6(9), Article ID e24407
6.
Kang Y, Jo J, Cho M, Yu H, Leem S, Song KS et al (2013) Trichinella spiralis infection reduces tumor growth and metastasis of B16-F10 melanoma cells. Vet Parasitol 196:106–113CrossRefPubMed
7.
Zou J, Huang XX, Yin GW, Ding Y, Liu XY, Wang H, Chen QJ, Suo X (2011) Evaluation of Toxoplasma gondii as a live vaccine vector in susceptible and resistant hosts. Parasit Vectors 4:168CrossRefPubMedPubMedCentral
8.
Ubillos L, Freire T, Berriel E, Chiribao ML, Chiale C, Festari MF, Medeiros A, Mazal D, Rondán M, Bollati-Fogolín M, Rabinovich GA, Robello C, Osinaga E (2016) Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers. Int J Cancer 138:1719–1731CrossRefPubMed
9.
Eissa MM, Allam SR, El-Mahdi AR, El-Azzouni MZ (2000) Autoclaved cercarial vaccine against schistosomiasis: ultrastructural and biochemical analysis. Southeast Asian J Trop Med Public Health 31(1):8–15 11414466PubMed
10.
11.
Eissa MM, Allam SR, El-Azzouni MZ, Maged HR, Dessouky IS (2003) Further studies on autoclaved cercarial vaccine against schistosomiasis safety, longevity and stability. J Egypt Soc Parasitol 33:541–560PubMed
12.
Hakomori S (2003) Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 491:369–402CrossRef
13.
Baldus SE, Engelmann K, Hanisch FG (2004) MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 41(2):189–231CrossRefPubMed
14.
Eissa MM, El-Azzouni MZ, Bolous LM (2003) Vaccination trial against experimental trichinosis using autoclaved Trichinella spiralis larva vaccine. J Egypt Soc Parasitol 33:219–228PubMed
15.
16.
Pellegrino J, Katz N (1968) Experimental chemotherapy of schistosomiasis mansoni. Adv Parasitol 6:233–290CrossRefPubMed
17.
Pica-Mattoccia L, Cioli D (2004) Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol 34:27–533CrossRef
18.
Wasson DL, Dougherky DA, Dick TA (1988) T. Spiralis induced by different Trichinella isolates. J Parasitol 74(2):283–287CrossRef
19.
20.
21.
Lowry OH, Rosebrough NS, Fan AL, Randall RS (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
22.
Thurnherr N, Deschner EE, Stonehill EH, Lipkin M (1973) Induction of adenocarcinomas of the Colon in mice by weekly injections of 1,2-Dimethylhydrazine. Cancer Res 33:940–945PubMed
23.
Darani HY, Curtis RH, McNeice C, Price HP, Sayers JR, Doenhoff MJ (1997) Schistosoma mansoni: anomalous immunogenic properties of a 27 kDa larval serine protease associated with protective immunity. Parasitology 115(3):237–247CrossRefPubMed
24.
Wang XL, Fu BQ, Yang SJ, Wu XP, Cui GZ, Liu MF, Zhao Y, Yu YL, Liu XY, Deng HK, Chen QJ, Liu MY (2009) Trichinella spiralis-A potential anti-tumor agent. Vet Parasitol 159:249–252CrossRefPubMed
25.
Piatier-Tonneau D (2002) CD Guide: CD4. In Mason D, Andre P, Bensussan A, Buckley C, Civin C & Clark E, et al. (Eds) Leucocyte typing VII. White cell differentiation antigens. Proceedings of the 7th International Workshop and Conference. Harrogate, United Kingdom, 19–23 June 2002; New York, Oxford University Press
26.
Alberici P (2007) The adenoma-carcinoma sequence in colorectal Cancer: scratching the surface. PrintPartners Ipskamp, Enschede, The Netherlands Library of the University of Oregon
27.
Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, Shyr Y, Beauchamp RD (2001) Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 61:5389–5395PubMed
28.
Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, Tsaur I, Blaheta R, Heemann U, Germer CT, Waaga-Gasser AM, Gasser M (2013) Expression of Foxp3 in colorectal Cancer but not in Treg cells correlates with disease progression in patients with colorectal Cancer. PLoS One 8(1):e53630CrossRefPubMedPubMedCentral
29.
Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gönner U, Wilsberg V, Junginger T, Berger MR, Galle PR, Moehler M (2005) Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behaviour of human colorectal cancer. Clin Cancer Res 11:1743–1750CrossRefPubMed
30.
31.
32.
Matisz CE, McDougall JJ, Sharkey KA, McKay DM (2011) Helminth parasites and the modulation of joint inflammation. J Parasitol Res 942616
33.
Ladoire S, Martin F, Ghiringhelli F (2011) Prognostic role of FOXP3+ regulatory T-cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60:909–918CrossRefPubMed
34.
Ondondo B, Jones E, Godkin A, Gallimore A (2013) Home sweet home: the tumor microenvironment as a haven for regulatory T cells. Front Immunol 4(197)
35.
Hesse M, Piccirillo CA, Belkaid Y, Prufer J, Mentink-Kane M, Leusink M, Cheever AW, Shevach EM, Wynn TA (2004) The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol 172:3157–3166CrossRefPubMed
36.
Marinho FV, Alves CC, de Souza SC, da Silva CM, Cassali GD, Oliveira SC et al (2016) Schistosoma mansoni tegument (Smteg) induces IL-10 and modulates experimental airway inflammation. PLoS One 11(7):e0160118CrossRefPubMedPubMedCentral
37.
Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello P, Prisco D, Novelli F, D’Elios MM (2013) Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother 62:1249–1260CrossRefPubMed
38.
Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R et al (2006) Cd4+ cd25+ foxp3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 1:e129CrossRefPubMedPubMedCentral
39.
Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S (2010) Tumor-infiltrating t-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222:350–366CrossRefPubMedPubMedCentral
40.
41.
Urban JF, Katona IM, Paul WE, Finkelman FD (1991) Interleukin 4 is important in protective immunity to a gastrointestinal nematode infection in mice. Proc Natl Acad Sci U S A 88(13):5513–5517CrossRefPubMedPubMedCentral
42.
43.
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favourable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538–18543CrossRefPubMedPubMedCentral
44.
Berriel E, Hill M, Barcia JJ, Ubillos L, Gonza’lez M, Detjen G et al (2005) Simple mucin-type cancer associated antigens are pre-cancerous biomarkers during 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Oncol Rep 14:219–228PubMed
45.
46.
Thors C, Jansson B, Helin H, Linder E (2006) Thomsen-Friedenreich oncofetal antigen in Schistosoma mansoni: localization and immunogenicity in experimental mouse infection. Parasitology 132:73–81CrossRefPubMed
47.
Wolf DA, Wang S, Panzica MA, Bassily NH, Thompson NL (1996) Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 56:5012–5022PubMed
48.
Ortega-Pierres MG, Yepez-Mulia L, Homan W, Gamble HR, Lim PL, Takahashi Y et al (1996) Workshop on a detailed characterization of Trichinella spiralis antigens: a platform for future studies on antigens and antibodies to this parasite. Parasite Immunol 18(6):273–284CrossRefPubMed
Metadata
Title
Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer
Authors
Maha M. Eissa
Cherine A. Ismail
Mervat Z. El-Azzouni
Amany A. Ghazy
Mona A. Hadi
Publication date
01-02-2019
Publisher
Springer US
Published in
Investigational New Drugs / Issue 1/2019
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-018-0609-6

Other articles of this Issue 1/2019

Investigational New Drugs 1/2019 Go to the issue

REVIEW

Advanced development of ErbB family-targeted therapies in osteosarcoma treatment

PRECLINICAL STUDIES

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

PRECLINICAL STUDIES

Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists

PHASE I STUDIES

Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects

PHASE I STUDIES

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

PRECLINICAL STUDIES

Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology – phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits